PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22098637-5	2011	Neither ceftriaxone nor ceftizoxime was detected in the plasma and urine of goats without Fibrosin( ) treatment, however, ceftriaxone persisted for 36 h and ceftizoxime was present from 48 h to 72 h in the plasma of Fibrosin( ) treated goats.	Ceftizoxime	157-168	LOW QUALITY PROTEIN: probable fibrosin-1	Capra hircus	216-225
22098637-6	2011	Ceftizoxime was also available from 72 h to 360 h post-dosing in milk in the presence of Fibrosin( ) following intramammary administration of ceftriaxone suggesting the polyherbal drug played a major role in the penetration of ceftriaxone from milk to systemic circulation.	Ceftizoxime	0-11	LOW QUALITY PROTEIN: probable fibrosin-1	Capra hircus	89-98
17344354-0	2007	Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney.	Ceftizoxime	53-64	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	15-19
17344354-7	2007	The urinary recovery of ceftizoxime was significantly reduced in Mrp4(-/-) mice, whereas it was unchanged for cefazolin.	Ceftizoxime	24-35	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	65-69
19936109-12	2009	It is concluded that ESBL-producing bacteria were prevalent among our hospitalized patients, and involved genera other than Klebsiella and Escherichia, and the inclusion of ceftizoxime increased the efficacy of ESBL detection by the DDD test.	Ceftizoxime	173-184	EsbL	Escherichia coli	211-215
17344354-8	2007	The kidney-to-plasma concentration ratio of ceftizoxime and cefazolin was increased 2.0- and 2.7-fold in Mrp4(-/-) mice, respectively; thus, the renal clearance with regard to the kidney concentration was reduced in Mrp4(-/-) mice, to 7.5 and 34% of the corresponding control values, respectively.	Ceftizoxime	44-55	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	105-109
17344354-0	2007	Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney.	Ceftizoxime	53-64	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	21-26
17344354-8	2007	The kidney-to-plasma concentration ratio of ceftizoxime and cefazolin was increased 2.0- and 2.7-fold in Mrp4(-/-) mice, respectively; thus, the renal clearance with regard to the kidney concentration was reduced in Mrp4(-/-) mice, to 7.5 and 34% of the corresponding control values, respectively.	Ceftizoxime	44-55	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	216-220
17344354-4	2007	Significant ATP-dependent transport of ceftizoxime (K(m), 18 microM), cefazolin (K(m), 80 microM), cefotaxime, and cefmetazole has been observed only in the membrane vesicles expressing hMRP4.	Ceftizoxime	39-50	ATP binding cassette subfamily C member 4	Homo sapiens	186-191
17344354-9	2007	These results suggest that Mrp4 is involved in the tubular secretion of ceftizoxime and cefazolin, in concert with basolateral uptake transporters.	Ceftizoxime	72-83	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	27-31
16098483-1	2005	We examined the substrate specificity of human organic anion transporter (hOAT) 1 and hOAT3 for various cephalosporin antibiotics, cephaloridine, cefdinir, cefotiam, ceftibuten, cefaclor, ceftizoxime, cefoselis and cefazolin by using HEK293 cells stably transfected with hOAT1 or hOAT3 cDNA (HEK-hOAT1, HEK-hOAT3).	Ceftizoxime	188-199	solute carrier family 22 member 6	Homo sapiens	47-81
16098483-1	2005	We examined the substrate specificity of human organic anion transporter (hOAT) 1 and hOAT3 for various cephalosporin antibiotics, cephaloridine, cefdinir, cefotiam, ceftibuten, cefaclor, ceftizoxime, cefoselis and cefazolin by using HEK293 cells stably transfected with hOAT1 or hOAT3 cDNA (HEK-hOAT1, HEK-hOAT3).	Ceftizoxime	188-199	solute carrier family 22 member 8	Homo sapiens	86-91
15716453-1	2005	Ceftizoxime, a beta-lactam antibiotic with high selective affinity for penicillin-binding protein 2 (PBP2) of Staphylococcus aureus, was used to select a spontaneous resistant mutant of S. aureus strain 27s.	Ceftizoxime	0-11	AT695_RS10295	Staphylococcus aureus	71-99
15716453-1	2005	Ceftizoxime, a beta-lactam antibiotic with high selective affinity for penicillin-binding protein 2 (PBP2) of Staphylococcus aureus, was used to select a spontaneous resistant mutant of S. aureus strain 27s.	Ceftizoxime	0-11	AT695_RS10295	Staphylococcus aureus	101-105
12016852-3	1998	The pharmacokinetic profile of chlorzoxazone(CZX), a drug probe for CYP2E1, was obtained after a single oral dose of 50 mg.kg-1.	Ceftizoxime	45-48	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	68-74
15716453-2	2005	The stable resistant mutant ZOX3 had an increased ceftizoxime MIC and a decreased affinity of its PBP2 for ceftizoxime and produced peptidoglycan in which the proportion of highly cross-linked muropeptides was reduced.	Ceftizoxime	107-118	AT695_RS10295	Staphylococcus aureus	98-102
3302857-0	1987	[In vitro antibacterial activity of ceftizoxime on Pasteurella and EF4].	Ceftizoxime	36-47	GTP binding elongation factor GUF1	Homo sapiens	67-70
8517725-1	1993	Klebsiella pneumoniae NU2936 was isolated from a patient and was found to produce a plasmid-encoded beta-lactamase (MOX-1) which conferred resistance to broad spectrum beta-lactams, including moxalactam, flomoxef, ceftizoxime, cefotaxime, and ceftazidime.	Ceftizoxime	214-225	beta-lactamase	Klebsiella pneumoniae	100-114
8517725-1	1993	Klebsiella pneumoniae NU2936 was isolated from a patient and was found to produce a plasmid-encoded beta-lactamase (MOX-1) which conferred resistance to broad spectrum beta-lactams, including moxalactam, flomoxef, ceftizoxime, cefotaxime, and ceftazidime.	Ceftizoxime	214-225	mesenchyme homeobox 1	Homo sapiens	116-121
35094207-2	2022	In the present study, not only did we evaluate the binding strength of ceftriaxone and ceftizoxime to bovine serum albumin (BSA), but we also investigated the kinetic and thermodynamic parameters including KD, KA, DeltaS, and DeltaH.	Ceftizoxime	87-98	albumin	Homo sapiens	109-122
35094207-9	2022	Finally, molecular docking confirmed that the preferable binding sites of ceftizoxime and ceftriaxone were site IIA and site IB of albumin, respectively.	Ceftizoxime	74-85	albumin	Homo sapiens	131-138
35073796-4	2022	Prior exposure to melittin did not reduce the MIC of the quinolones tested, but it decreased the MIC of ceftizoxime by 8-fold due to its ability to form pores in the membrane.	Ceftizoxime	104-115	melittin	Apis mellifera	18-26
3302857-1	1987	The in vitro activity of ceftizoxime, a new third-generation cephalosporin, was tested by determining minimal inhibitory concentrations (MIC) by agar dilution method, for 150 strains of genus Pasteurella and group EF4 bacteria from various sources.	Ceftizoxime	25-36	GTP binding elongation factor GUF1	Homo sapiens	214-217
6097357-8	1984	The findings indicate that ceftizoxime, 1 to 2 gm BID, is effective and safe in the treatment of lower respiratory tract infections in hospitalized patients.	Ceftizoxime	27-38	BH3 interacting domain death agonist	Homo sapiens	50-53
6098179-5	1984	No serious side effects were observed in the clinical or laboratory findings except for slight elevation in GOT & GPT values in two cases (2.5%), which returned to normal after CZX treatment.	Ceftizoxime	181-184	glutamic--pyruvic transaminase	Homo sapiens	118-121
3480076-0	1987	Measurement of C-reactive protein to compare ceftizoxime versus cefoxitin/doxycycline therapy for septic pelvis: a preliminary report.	Ceftizoxime	45-56	C-reactive protein	Homo sapiens	15-33
3480076-2	1987	In a study comparing ceftizoxime and cefoxitin/doxycycline in patients with septic pelvis, quantitative CRP levels were closely correlated with the responses and failures of therapy.	Ceftizoxime	21-32	C-reactive protein	Homo sapiens	104-107
31949454-5	2019	Results: ESBL-producing samples had higher antibiotic resistance rates than ESBL-non-producing samples: ceftriaxone (58.8% vs. 27.3%), cefotaxime (73.5% vs. 30.3%), ceftizoxime (76.5% vs. 33.3%), cefixime (79.4% vs. 40.9%), and cefpodoxime (73.5% vs. 53%), except for carbenicillin (29.4% vs. 48.5%).	Ceftizoxime	165-176	EsbL	Escherichia coli	9-13
33568029-5	2021	On the other hand, ceftizoxime (active metabolite of ceftriaxone) achieved a peak level of 55.42+-3.34 microg mL-1 at 72 h and could not be detected at 120 h post drug administration in the milk of thosemastitic crossbred cows.	Ceftizoxime	19-30	L1 cell adhesion molecule	Mus musculus	110-114
6284650-1	1982	After the cytology and the chemistry of the CSF had returned to normal, the concentration of ceftizoxime was determined in the CSF and in the serum of 27 patients who had suffered from purulent or serous meningitis.	Ceftizoxime	93-104	colony stimulating factor 2	Homo sapiens	127-130
6284650-3	1982	The concentration in the CSF was mean = 0.87 mg/l two hours after a bolus injection of 2 g ceftizoxime.	Ceftizoxime	91-102	colony stimulating factor 2	Homo sapiens	25-28
6284650-4	1982	After an infusion of 2 g ceftizoxime over 30 minutes, the concentration in the CSF was mean = 0.32 mg/l one hour and mean = 0.99 mg/l two hours after the infusion was started.	Ceftizoxime	25-36	colony stimulating factor 2	Homo sapiens	79-82
6284650-5	1982	The highest concentrations in the CSF were obtained six hours after a bolus injection of 2 g ceftizoxime.	Ceftizoxime	93-104	colony stimulating factor 2	Homo sapiens	34-37
6284650-7	1982	Based on these pharmacokinetic data, additional injections could have a cumulative effect on the concentration of ceftizoxime in the CSF.	Ceftizoxime	114-125	colony stimulating factor 2	Homo sapiens	133-136
6279908-19	1982	A mild increase in GOT and GPT was observed in 1 patient during treatment with CZX, and the values returned to normal after discontinuation of the drug.	Ceftizoxime	79-82	glutamic--pyruvic transaminase	Homo sapiens	27-30
26724739-9	2016	Ceftizoxime increased slightly ebpA (+19.7%) and reduced others (asa1:-66.2%, esp:-35%, ace:-28.1%, efaA:-38.4%).	Ceftizoxime	0-11	aggregation substance	Enterococcus faecalis	65-69